Automated assay evaluates motility inhibition of Fasciola hepatica miracidia, indicating drug efficacy against the parasite.
Key Points
Motility inhibition was observed in F. hepatica miracidia exposed to CLOS, TCBZ, and TCBZ-SO, with varying effectiveness.
CLOS showed the highest potency against isolates from New South Wales, Tasmania, and Victoria, while TCBZ and TCBZ-SO had isolate-specific sensitivity.
Automated miracidial motility assay developed using WMicroTracker ONE effectively quantifies sensitivity in vitro.
The findings highlight the assay's reproducibility and host-independent nature, enhancing drug efficacy assessment.